Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-9057
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HRS-9057 is a novel small molecule drug under development for the treatment of heart failure with volume overload, body fluid retention, and autosomal dominant polycystic kidney disease (ADPKD). It is being investigated in both oral tablet and injectable formulations. The mechanism of action has not been fully disclosed but preclinical data suggest it may inhibit excessive kidney cell proliferation and vesicle formation in ADPKD. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers as well as patients with heart failure and volume overload[1][2][5][9].
Beyond the preview
Go deeper on HRS-9057.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-9057.